… Disease targeting B4GALT1 Development of Axiomer ® RNA base editing technology platform continues across multiple … against a key Axiomer patent protecting ADAR-mediated RNAediting Well-capitalized with €139 M, in cash and cash …
Post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when comparing active treatment and sham eyes to their corresponding contralateral eyes across multiple endpoints – Company plans to discuss findings with regulators in Q3
… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNAediting technology platform, today announced that Company …
… company dedicated to changing lives through transformative RNA therapies, today announced it will present preclinical data for its proprietary Axiomer™ RNAediting technology platform and its AX-0810 pipeline program …
… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer ™ RNAediting technology platform today announced that Company …
… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNAediting technology platform, today announced the Annual …
Find all relevant presentations and publications for each of our programs. From review papers to preclinical posters and clinical data presentations at medical conferences.
